The FDA approved Theravance Inc's antibiotic lung drug (bacterial pneumonia) Vibativ
Vibativ is already approved in Europe for the treatment of adults with nosocomial pneumonia.
Report that GlaxoSmithKline is lining up a $55 per share bid for Theravance.
In the U.S. and Canada it is approved only for pneumonias related to staph. for people on ventilators where no other treatment has helped. I suspect it will not have much effect on the sales of Arikace.
McGill University and GlaxoSmithKline plc (GSK) have signed a collaboration agreement to develop a potential breakthrough approach to treat cystic fibrosis, a fatal genetic disease. The trans-Atlantic effort between researchers from McGill's Faculty of Medicine and their GSK collaborators in the UK, will focus on developing molecules that could treat the disease by correcting the dysfunction caused by the mutated gene. This revolutionary approach will be a departure from current treatments, which only manage the symptoms or complications of the disorder. The collaborative research is co-sponsored by the Canadian Institutes of Health Research (CIHR).
From an October, 2012 article by the researcher at McGill entitled, "Fixing Cystic Fibrosis by correcting CFTR domain assembly."
In this paper we have described the cellular consequences of CFTR mutations and recent efforts to understand the folding defects underlying the F508-CFTR mutation in order to improve channel folding, stability, and function. However, many critical issues remain. Our understanding of how the loss of channel function results in CF, particularly the lung symptoms, is incomplete (Ashlock and Olson, 2011) and compounded by the fact that mouse models fail to recapitulate the CF lung
disease, though the development of transgenic pig and ferret might address this issue (Rogers et al., 2008; Sun et al., 2010).
The ultimate success of translational research most often relies on our detailed understanding of the basic biological problem at hand. We hope that this short perspective will help inspire further biological research, a prerequisite for translational successes in curing basic defects in CF...
Doesn't sound like they are on the verge of a breakthrough therapy yet.